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BACKGROUND: Noninvasive imaging of atherosclerosis
is being increasingly used in clinical practice, with some
experts recommending to screen all healthy adults for
atherosclerosis and some jurisdictions mandating in-
surance coverage for atherosclerosis screening. Data on
the impact of such screening have not been systemat-
ically synthesized.
OBJECTIVES: We aimed to assess whether atheroscle-
rosis screening improves cardiovascular risk factors
(CVRF) and clinical outcomes.
DESIGN: This study is a systematic review.
DATA SOURCES: We searched MEDLINE and the
Cochrane Clinical Trial Register without language
restrictions.
STUDY ELIGIBILITY CRITERIA: We included studies
examining the impact of atherosclerosis screening with
noninvasive imaging (e.g., carotid ultrasound, coronary
calcification) on CVRF, cardiovascular events, or mor-
tality in adults without cardiovascular disease.
RESULTS: We identified four randomized controlled
trials (RCT, n=709) and eight non-randomized studies
comparing participants with evidence of atherosclerosis
on screening to those without (n=2,994). In RCTs,
atherosclerosis screening did not improve CVRF, but
smoking cessation rates increased (18% vs. 6%, p=
0.03) in one RCT. Non-randomized studies found
improvements in several intermediate outcomes, such
as increased motivation to change lifestyle and in-
creased perception of cardiovascular risk. However,
such data were conflicting and limited by the lack of a
randomized control group. No studies examined the
impact of screening on cardiovascular events or mor-
tality. Heterogeneity in screening methods and studied
outcomes did not permit pooling of results.
CONCLUSION: Available evidence about atherosclerosis
screening is limited, with mixed results on CVRF
control, increased smoking cessation in one RCT, and
no data on cardiovascular events. Such screening
should be validated by large clinical trials before
widespread use.
KEY WORDS: atherosclerosis; diagnostic techniques; cardiovascular;
coronary disease; health behavior; smoking cessation; clinical trial;
systematic review.
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BACKGROUND
Several techniques of noninvasive vascular imaging have been
proposed in recent years as tools for detecting asymptomatic
atherosclerosis without overt cardiovascular disease (CVD).1–3
Some measures of atherosclerosis have been shown to improve
the prediction of coronary heart disease (CHD) events.4–7
However, good prediction does not necessarily lead to effective
prevention.8,9 Among the important criteria to assess their
potential clinical value, novel markers of cardiovascular risk
should be assessed by their effect on patient management and
outcomes.10
Screening for atherosclerosis and knowing the test result
might help enhance patient motivation to change unhealthy
behaviors,11,12 such as smoking, or improve lifestyle and
adherence to medications. In 2003, a review for the U.S.
Preventive Services Task Force (USPSTF) identified only two
studies that examined the impact of coronary artery calcifica-
tion [CAC, by computed tomography (CT)] screening on risk-
reducing behaviors.13 These two studies were not random-
ized,14,15 and behavior outcomes were self-reported. Since this
publication, new studies16–18 or studies with other screening
techniques11 have been published.
A substantial amount of controversy remains about the role
of screening for atherosclerosis in the clinical setting.19 Some
groups have suggested that imaging should be considered only
in certain subgroups of patients, while others advocate a more
widespread application (Table 1). Some experts have even
suggested screening most healthy adults for atherosclerosis.3
Such screening is being increasingly used in clinical practice to
screen asymptomatic adults.12,13,20–22 Moreover, insurance
coverage for atherosclerosis screening with carotid ultrasound
is under consideration;23 the Texas Legislature passed a new
law, effective Jan 1, 2010, mandating broad insurance cover-
age for atherosclerosis screening, which could lead to a
considerable increase in screening.19 Therefore, a systematic
review was performed to assess whether screening for athero-
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Table 1. Recommendations on Screening for Atherosclerosis in Asymptomatic Adults
Organization, publication year Imaging method Screening recommendation per group
Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel
on Detection, Evaluation, And Treatment
of High Blood Cholesterol In Adults
(Adult Treatment Panel III), 200253
CAC Persons with no CVRFs: Not recommended
CAC is an option for advanced risk assessment in appropriately
selected persons
Multiple CVRFs: High CAC score provides a rationale for intensified
LDL-lowering therapy
Elderly: High CAC score could help decide to introduce LDL-lowering
drugs for primary prevention
American Diabetes Association, 200354 ABI ABI should be performed in diabetics >50 years. If normal, ABI
to be repeated every 5 years
ABI should be considered in diabetics <50 years if other PAD risk
factors (e.g., smoking, hypertension, hyperlipidemia, or duration
of diabetes >10 years)
International Task Force for Prevention
of Coronary Heart Disease, 200555
CAC and carotid
ultrasound
CAC recommended in most persons. Lowering of target LDL-
cholesterol according to results of screening
Society of Heart Attack Prevention
and Eradication (SHAPE), 20063*
CAC and carotid
ultrasound
Screening every 5 years all men aged 45–75 years and women
aged 55–75 years who have at least one CVRF
ACC/AHA 2005 guidelines for the
management of patients with
peripheral arterial disease, 200656
ABI Detection of asymptomatic lower extremity PAD should be identified
by examination and/or measurement of the ABI (class I
recommendation, Level of evidence: B)†
Joint Task Force of the European
Society of Cardiology and
other societies on cardiovascular
disease prevention in clinical
practice, 200757
CAC Intermediate-risk persons‡ can be useful to target treatment
MRI Not enough evidence to recommend use to detect coronary
artery stenoses
Carotid ultrasound Carotid ultrasound can add information beyond assessment of
traditional risk factors, which may help make decisions about
medical therapy for primary prevention. Uncertainty regarding
formal incorporation into existing algorithms used in
asymptomatic persons
U.S. Preventive Services Task Force
(USPSTF), 200949
CAC, ABI, carotid
ultrasound
Not enough evidence to determine the balance between benefits
and harms of using non-traditional risk factors for CHD
risk assessment (I Statement: insufficient evidence)‡
2010 ACCF/AHA Guideline for
Assessment of Cardiovascular Risk
in Asymptomatic Adults, 201048‖
Carotid ultrasound
and ABI
Measurement may be reasonable in intermediate-risk
adults§ (class IIa Recommendation, Level of evidence: B)†
CAC Measurement may be reasonable in intermediate-risk adults
and in diabetics ≥40 years (class IIa Recommendation, Level
of evidence: B)†
Measurement might be reasonable in low- to intermediate-risk
adults‡ (6–10% 10-year risk; class IIb Recommendation,
Level of evidence: B)†
Angio CT Persons at low risk (<6% 10-year risk) should not undergo
CAC measurement (class III—no benefit Recommendation,
Level of evidence: B)
Working Group on Nuclear Cardiology
and Cardiac CT of the European Society
of Cardiology, 201058
CAC CAC should be considered in intermediate-risk adults: high
calcium scores identify subjects at high risk who may benefit
from aggressive secondary prevention strategies
Coronary CT angiography currently not recommended as a
screening tool in asymptomatic adults
ACCF/SCCT/ACR/AHA/ASE/ASNC/
NASCI/SCAI/SCMR Appropriate
Use Criteria for Cardiac Computed
Tomography 201059
CAC Appropriateness¶ according to CHD risk§
Low-risk persons: Inappropriate
Intermediate-risk persons: Appropriate
High-risk persons: Uncertain
Low-risk persons with family history of premature CHD:
Appropriate
Angio CT Low-risk persons: Inappropriate
Intermediate-risk persons: Inappropriate
High-risk persons: Uncertain
CVD cardiovascular disease, CHD coronary heart disease, ABI ankle–brachial index, CVRF cardiovascular risk factor, EBCT electron beam
computer tomography, CAC coronary artery calcification, PAD peripheral artery disease, ACC American College of Cardiology, ACCF American
College of Cardiology Foundation, AHA American Heart Association, SCCT Society of Cardiovascular Computed Tomography, ACR American
College of Radiology, ASE American Society of Echocardiography, ASNC the American Society of Nuclear Cardiology, NASCI North American
Society for Cardiovascular Imaging, SCAI Society for Cardiovascular Angiography and Interventions, SCMR Society for Cardiovascular Magnetic
Resonance
*The SHAPE Task Force has issued a press release, reacting to the new ACCF/AHA 2010 guidelines for Assessment of Cardiovascular Risk in
Asymptomatic Adults coronary, stating that: CIMT or CACS are recommended for intermediate-risk adults aged 45–80 and men ≥35 with diabetes or have
family history of premature coronary disease, and to be repeated every 3–5 years, depending on risk level assessed at the first test60
†Classification of recommendations and Level of Evidence according to ACC/AHA Guideline Writing Committees
‡Grades of recommendations according to the USPSTF
§Low CHD risk: 10-year absolute CHD risk <10%. Intermediate CHD risk: 10-year CHD risk 10–20%. Among women and younger men, an expanded
intermediate risk of 6–20% may be appropriate. High CHD risk: presence of diabetes mellitus in a patient ≥40 years, peripheral arterial disease or other
coronary risk equivalents, or the 10-year absolute CHD risk >20%
‖The ACC/AHA made these recommendations, recognizing the absence of current evidence for improved net health outcomes: no evidence is available to
show that risk assessment using atherosclerosis screening improves clinical outcomes by reducing mortality or morbidity from CAD48
¶Appropriate test: generally acceptable and a reasonable approach for the indication. Uncertain test for specific indication: generally acceptable
and may be a reasonable approach for the indication. Inappropriate test for specific indication: not generally acceptable and not a reasonable
approach for the indication
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sclerosis improves cardiovascular risk factors (CVRF) and
clinical outcomes.
METHODS
Study Selection
Studies had to meet four inclusion criteria: (1) the study
population had to be adults without preexisting CVD [myocar-
dial infarction, stroke, transient ischemic attack, or peripheral
arterial disease (PAD)]; (2) imaging of atherosclerosis had to be
done by noninvasive techniques,20 such as ultrasonography
(carotid intima–media thickness or carotid plaques), conven-
tional abdominal radiography (aortic calcifications), CT (CAC),
ankle/brachial index (ABI), or flow-mediated brachial artery
endothelial vasodilatation to assess endothelial dysfunction;
(3) studies had to report follow-up clinical events, such as all-
cause or cardiovascular (CV) mortality, acute coronary syn-
drome (ACS), stroke, documented PAD, or intermediate clinical
outcomes, such as CVRF control (smoking cessation, blood
lipid control, diet change, weight reduction, or physical activity
improvement) or changes in health behavior (e.g., increased
motivation to change lifestyle, increased perception of cardio-
vascular risk, adherence to medication); and (4) the interven-
tion group had to be compared with a control group of adults
who did not receive the screening intervention (randomized
controlled trials, RCTs) or a control group who did not have
evidence of atherosclerosis upon screening, as reported in
available non-randomized studies; these non-randomized
studies did not report comparisons with a control group of
adults who were not screened for markers of atherosclerosis.
The search strategy was not limited to RCTs because of the
likely low numbers of such studies13 and to assess whether
observational studies showed patterns that might be consis-
tent with potential impact of atherosclerosis screening. Studies
that assessed the impact of surgical procedures (e.g., screen-
ing for aortic aneurysm followed by surgery) were excluded.
The numerous studies that assessed risk prediction of athero-
sclerosis markers5 or that assessed cardiac stress imaging
tests were not included as such studies have been previously
reviewed.24–27 We did not include studies that only examined
changes in prescription rates of CV preventive medications
(e.g., aspirin, statins) after atherosclerosis screening since
prescription rates are mainly related to physicians’ decisions;
the aim of the present systematic review was to assess whether
the results of screening given to patients lead to increased
motivation12 (e.g., lifestyle changes, adherence rates to CV
preventive medication), with subsequent improvement in
CVRF control and clinical outcomes. If follow-up outcomes
other than prescription rates were reported, such studies were
not excluded.
Outcomes
The primary outcomes were clinical events, such as all-
cause and CV mortality, ACS, stroke, documented PAD, or
a change in CVRF control at follow-up (i.e., differences in
smoking cessation rates, lipid, and blood pressure
changes). Secondary outcomes were modification in adher-
ence rates to CV preventive medication, risk perception of
developing heart disease, quality of life, and changes in
health behavior (e.g., increased motivation to change
lifestyle, physical activity, diet).
Search Strategy
MEDLINE (1966 through April 2009) and the Cochrane
Controlled Clinical Trial register (1996 through April 2009)
were searched using a recommended approach for systematic
reviews of RCTs with a predefined search strategy.28 All
languages were considered eligible. For MEDLINE, three
comprehensive search themes were combined using the
Boolean operator “and.” The first theme representing the
patient population of interest was created using the following
terms which appeared as exploded MeSH headings—CV dis-
eases/prevention and control—or as text words—coronary or
aortic or aorta. The second theme for the screening method of
interest used the following terms—magnetic resonance angi-
ography or radiography, abdominal or radiography, thoracic or
tomography, x-ray, computed or ultrasonography, or ankle/
blood supply or brachial artery/blood supply—or the terms
appearing as text words—computed tomography or ultraso-
nography or ankle–brachial index, or flow-mediated vasodila-
tation. The third theme, which defined the outcome of interest,
was created using the exploded MeSH headings: counseling or
preventive health services or motivation or behavior, including
smoking cessation, as well as coronary disease and mortality
for RCTs. For the Cochrane Controlled Clinical Trial register, a
similar search strategy used text words, for which the com-
prehensive search themes “patient population,” “screening
method,” and “studied outcome” were combined using the
Boolean term “and.”
Data Extraction and Quality Assessment
In a two-step selection process, two investigators (RA and
VdB) independently reviewed the titles and abstracts of all
citations to identify studies meeting the inclusion criteria.
When in doubt about eligibility on the first screen, full-text
articles were obtained. Articles selected by either both or
only one author were selected for full-text review. In
addition, one investigator (RA) screened the reference list
of identified studies on the first screen and major reviews
on the topic for other potentially relevant studies.12,13,29–31
The same two investigators reviewed the relevant reports in
full text for eligibility and independently extracted data
from all studies fulfilling eligibility criteria. Data extraction
included characteristics of the screening intervention, type
of study, baseline clinical characteristics of the partici-
pants, and relevant outcomes. Authors of the studies were
contacted for additional information when needed.32
Study design was considered as the primary study quality
measure;33 studies with a control group that did not receive
the screening intervention (RCTs) were considered stronger
than those with a control group that had the screening
intervention but did not present evidence of atherosclerosis
(non-randomized studies). For the RCTs, the Jadad quality
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score was reported, adapting it to the present situation;34
blinding of study participants to intervention was not includ-
ed as this is difficult to achieve in studies of lifestyle
interventions. Items used to assess study quality were:
methods of randomization (two points) and reporting of losses
to follow-up (one point), thus leading to a maximum score of
three points.
Statistical Analysis
A flowchart summarized the number of trials identified,
excluded and included. Due to major variations in both
screening methods and studied outcomes, the results were
not combined in a meta-analysis and only individual study
results were reported.
RESULTS
A total of 2,634 unique citations were identified, including
1,783 from MEDLINE and 851 additional from the Cochrane
Controlled Clinical Trial register (Fig. 1). After a two-step
screening process, 12 articles fulfilled the inclusion crite-
ria.11,14–18,32,35–39 Using the abstract and title on the first
screen, 13 disagreements concerning eligibility for a full-text
review occurred between the two reviewers (kappa=0.81). For
the second screen, which was based on the full-text review of
41 studies, there was one disagreement (kappa=0.94). This
disagreement was resolved by consensus.
RCTs Comparing Participants Randomized
to Atherosclerosis Screening
Four RCTs included a total of 709 participants.11,16,32,35
Heterogeneity in screening methods and the studied outcomes
did not allow pooling of results or description of overall results.
Semiquantitative assessments of the study results are de-
scribed in Table 2. No RCTs examined the impact of screening
on CV events or mortality. Overall, screening for atherosclero-
sis did not improve CVRF, except for increased smoking
cessation rates (18% vs. 6%, p=0.03) in one RCT;11 other RCTs
included only few smokers (Table 3). Two RCTs found no
improvement on quality of life.
RCT of Carotid Ultrasound by Bovet et al.11. In 153 smokers
randomly allocated to carotid ultrasound, providing pictures of
their own atherosclerotic plaques improved the rates of smoking
cessation from 18% in the screened group vs. 6% in the group
without screening (p=0.03, Table 3) in addition to brief advice for
smoking cessation. The absence of biochemical validation of
smoking cessation was the major limitation of this trial. It was
undertaken in the Seychelles islands, in a population with low
Figure. 1. Flowchart of included studies. CVD cardiovascular disease.
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nicotine dependence (mean: ten cigarettes/day, about half the
amount as in Western countries). No other RCTs that evaluated
the effect of carotid ultrasound atherosclerotic plaque screening
on risk-reducing behavior were found.
RCT of CT by O’Malley et al.16. This RCT included 450
asymptomatic active-duty US Army personnel aged 39–
45 years.16 CAC screening by CT did not lead to improved
CVRF control or change in the Framingham Risk Score
(Table 3). This study has the highest Jadad quality score (3/3).
Screening had little effect on smoking rates (5/13 in
intervention vs. 4/17 in the control group), but few smokers
were randomized. Among its limitations, the study participants
were young adults with a low 10-year CHD risk of 6% and a low
prevalence of CAC (15%).12
A subgroup analysis showed that the presence of coronary
calcifications (“risk marker”) might be a motivating factor.
Among those with CAC (n=59), those who learned that they
had calcifications had a smaller, albeit non-statistically
significant, increase in the 10-year Framingham Risk Score
compared with those who did not receive such information
(0.21% vs. 1.52% increase in risk score, p=0.13).16 Another
potential limitation of this trial was the 2×2 factorial design with
two interventions (information on calcification vs. no
information intensive vs. usual care) as this may have had an
effect on the same outcomes; this might have biased the results
toward the null hypothesis.40
RCT of CT by Lederman et al.35. This study of 56 postmenopausal
women randomized to either CAC screening plus a counseling
session or the control group (conventional counseling) found
that the intervention CT group had less improvement in LDL-
cholesterol compared with the control group (Table 3). The high
proportion of women with low CAC score (mean score=1.37)
might partly explain the results as these women screened for
CAC might have been reassured that they were not at high risk
of CHD.
RCT of Total Body Scan by Obuchowski et al.32. In a pilot study,
50 white adults self-referred from advertisements were
randomized to total body scan with CAC screening or no
screening and followed for 2 years. Among 3 of the 25 screened
subjects who had a CAC score ≥100, cardiac catheterization
showed three-vessel occlusive disease in one patient who
subsequently underwent coronary bypass grafting; the two
others had normal cardiac stress testing and no clinical
events. No other participant had clinical events during follow-
up, but the small sample size limits the interpretation of the
results. Self-reported quality of life measured by the SF-36 did
not differ between screened and control subjects over time,
Table 2. Semiquantitative Assessment of Study Results
Study Imaging
method
Smoking cessation Risk
perception of
developing
heart disease
Improvement in Motivation
to make
lifestyle
changes
Quality
of life
Clinical
cardiovascular
outcomes
(CVD, CHD),
or mortality
Effect on
cessation/No.
(%) of smokers
Motivation
for smoking
cessation
Diet Physical
activity
Blood
lipids
Randomized controlled trials
Bovet et al.
(2002)11
Ultrasound ++
153 (100%)
O’Malley et al.
(2003)16
EBCT ↔ ↔ ↔ ↔ ↔ ↔
30 (7%)
Lederman et
al. (2007)35
DHCT ↔ ↔ –
2 (4%)
Obuchowski et
al. (2007)32
EBCT ↔
Non-randomized studies
Wong et al.
(1996)15
EBCT ↔ ++ ↔
(% NR)
OMalley et al.
(2002)14
EBCT ↔ ↔ ++
99 (100%)
Kalia et al.
(2006)17
EBCT ↔ ++ ↔ –*
53 (10%)
Sandwell et al.
(2006)39
EBCT ++ ++ ↔ ++
Wyman et al.
(2007)18
EBCT ++ ↔
Korcarz et al.
(2008)37
Ultrasound ++ ++
Orakzai et al.
(2008)38
EBCT ++ ++ –*
Rodondi et al.
(2008)36
Ultrasound ↔ +† ++
30 (100%)
Detailed results are provided in Tables 3 and 4
CAC coronary artery calcification, DHCT double helical computed tomography, CHD coronary heart disease, CVD cardiovascular disease, EBCT electron
beam computer tomography, ↔ No change, ++ increase or improvement, – less controlled, % NR % of smokers not reported
*Exclusion of participants with clinical outcomes
†Pattern of higher quit rates compared to those without plaques (73% vs. 38%, p=0.10)
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except for one of the eight subscales (fewer role limitation due
to physical health problem in screened subjects).
Non-randomized Studies with a Control Group
Without Evidence of Atherosclerosis at Screening
Two thousand nine hundred ninety-four participants were
included in eight non-randomized prospective or retrospective
studies comparing participants with evidence of atherosclero-
sis on screening to those without (Table 4). No studies
examined the impact of screening on CV events or mortality
or on quality of life. These studies assessed the impact of
atherosclerosis screening on patient behaviors and CVRFs.
Heterogeneity in screening methods and studied outcomes did
not permit pooling of results. Semiquantitative and detailed
assessments of the study results are described in Tables 2 and
4. Four studies found increased risk perception of developing
CHD. Four studies found self-reported improvement in diet.
However, two RCTs did not show an effect on improvement in
diet. One study found improvement in blood lipid levels, and
two of three studies showed increased motivation to make
lifestyle changes. One study found increased motivation for
smoking cessation in smokers with carotid plaques compared
to those without (8.7 vs. 7.2/10, p=0.008) and a pattern of
higher quit rates (73% vs. 38%, p=0.10);36 the three other
studies did not find improved smoking cessation rates.
Physical activity did not differ between the two groups, except
in one study. These behaviors were all self-reported.
Concerning drug adherence, one study found that individuals
with CAC scores in the fourth quartile were more likely
(multivariate-adjusted OR=9.26, 95%CI=4.13–20.76) to con-
tinue statins compared to those with CAC scores in the first
quartile.17 However, no formal measurement of adherence
such as drug dispensers with electronic monitoring or pill
count was performed. The study populations were often not
population-based as participants were frequently referred for
atherosclerosis screening by their general practitioner.
DISCUSSION
This systematic review found that available evidence about
atherosclerosis screening using noninvasive imaging was
limited and yielded mixed results. In the RCTs, screening for
atherosclerosis did not improve CVRF, but an increased
smoking cessation rate (18% vs. 6%, p=0.03) was found in a
single RCT.11 Non-randomized studies showed potential posi-
tive effects of atherosclerosis screening on “intermediate” out-
comes, such as increased motivation to change lifestyle36,37
and an increased perception of CV risk.14,18,37,39 However,
such data were based on self-report and limited by the lack of a
randomized control group. We found no studies that evaluated
the impact of screening on CV events or mortality. These
results are important in the context of substantial controversy
about the role of screening for atherosclerosis.19
Consistent with the results of atherosclerosis screening on
smoking cessation, mainly derived from the RCT by Bovet et
al.,11 a recent Cochrane review evaluated the impact of visual
feedback of medical images in changing health behavior41 and
reported a statistically significant increase in smoking cessa-
tion behaviors (OR=2.81, 95% CI=1.23–6.41) after pooling the
data from three studies.11,16,42 Because of the exclusion of
studies in patients with preexisting CVD, the present review
did not include the study by Shahab et al.42 and did not pool
data on smoking cessation behaviors because of clinical
heterogeneity (different timing for assessment of smoking
cessation behaviors, very few smokers in one RCT).16 These
data on smoking cessation behaviors require confirmation
with a larger RCT that includes smokers with higher daily
cigarette consumption than in the Seychelles islands,11 as well
as a biochemical validation of smoking cessation, one being
currently performed.43
Increased cardiovascular risk perception after atherosclero-
sis screening was found, consistent with recent systematic
review findings that receiving global CHD risk information
increased the accuracy in CHD risk perception.44 However, no
study compared the incremental effectiveness of providing
feedback on atherosclerosis imaging in addition to global
CHD risk. Moreover, data from the present review showing
increased CHD risk perception were all derived from non-
randomized studies. Overall, other results are also consistent
with this recent Cochrane review on feedback of medical
imaging described above.41 This review (that did not specifi-
cally examine atherosclerosis screening) found mixed results
concerning the impact of visual feedback of images on health
behavior. Risk perception and clinical events were not
assessed.
What are potential harms of atherosclerosis imaging? One
study showed an increase in anxiety levels after such screen-
ing,15 which was not found in two other studies16,43 (Tables 3
and 4). Another study found that atherosclerosis screening
may result in subsequent invasive testing and increased
healthcare utilization.32 However, other potential harms of
atherosclerosis screening, such as radiation exposure and
subsequent malignancy,8 were not assessed in the reviewed
studies. Another potential harm might be false reassurance,
with the pursuit of unhealthy lifestyle. The slightly lower
smoking cessation rate in those without plaques (5%) com-
pared with the non-screened group (6%) in one RCT11 might be
related to false reassurance, although data are conflicting on
the impact of false reassurance after a negative screening test.45
The major limitation of the present systematic review,
inherent to the available studies, is the small number of
available RCTs. The reported results mainly rely on data from
non-randomized studies, these studies showing more positive
results than RCTs, except for smoking cessation. There was also
clinical heterogeneity in the screening methods used and the
studied outcomes. The pooling results in this case seemed
inadequate. For smoking cessation, no studies provided a
confirmation of smoking cessation by biochemical validation,
as recommended.46 These limitations were inherent to the
available studies and confirm the need for more RCTs in this
field.47 No studies examined the impact of screening on CV
events or mortality. This is likely related to the need of a very
large sample size for such trials; the NHLBI working group has
estimated that a trial on the impact of such screening on clinical
cardiovascular events would likely require >10,000 partici-
pants.20
What are the potential clinical and research implications of
these findings? The mixed findings and limited data on
atherosclerosis screening are important in the context of
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controversy about the role of screening for atherosclerosis,19
with controversial recommendations (Table 1). Recognizing the
absence of current evidence for improved net health outcomes
from atherosclerosis screening, the ACC/AHA has recently
suggested that it may be reasonable to measure carotid
intima–media thickness (IMT) or CAC among asymptomatic
adults at intermediate CHD risk.48 The USPSTF did not
recommend any of the available imaging modalities.49 It is
common that new, often expensive, technologies do not undergo
formal evaluation prior to being implemented within standard of
care.50,51 Population-wide screening might concern a large
population, with substantial public health and cost implica-
tions.23 For example, the Society of Cardiovascular Computed
Tomography estimates that more than 200,000 Americans had
CAC screening in 2008 at a cost of about US $50million.22 Such
screening might become a profitable business, including some-
times by using patients’ concerns as the motor for screening.52
Cost effectiveness studies should assess whether costs associat-
ed with atherosclerosis screening23 and potential long-term
harms, suchas radiation exposure and subsequentmalignancy,8
might be outweighed by potential benefits, such as increased
smoking cessation and improved adherence (albeit with limited
data), more effective targeting of preventive therapy to those who
really need it, or a reduction in major cardiovascular events.47
Modelingmight help determine the screening procedures and the
target population to design future large-scale, expensive RCTs.47
Given limited RCTdata, scientific societies shouldmake cautious
recommendations on extensive use of atherosclerosis screening.
In summary, this systematic review shows that available
evidence about atherosclerosis screening using noninvasive
imaging is limited, with mixed results on CVRF control and
increased smoking cessation in a single RCT. Absence of proof of
benefit is certainly not proof of absence of benefit. However, the
potential advantages of atherosclerosis screening need to be
demonstrated by large-scale RCTs.8,50 Not conducting such trials
would leave clinicians with no scientific basis for making
decisions regarding newly proposed, and sometimes expensive,
methods for identifying high CHD risk adults.20,47 Such trials
should likely target intermediate-risk adults, as suggested by
others,1,20,47 and/or those with a high likelihood of atheroscle-
rosis,12 given the pattern of more benefits of atherosclerosis
screening in the small group with calcification in the highest
quality trial.16 Such trials should assess the impact of athero-
sclerosis screening on relevant clinical outcomes, including
cardiovascular risk factors, smoking cessation, and, ideally,
cardiovascular events,47 before its widespread implementation.
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